View Older Stories View More Recent Stories

Jun 3, 2024 07:32AM Arrowhead Pharmaceuticals (ARWR) Reports Successful Results for Plozasiran from the Phase 3 PALISADE Study
Jun 3, 2024 07:30AM Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
May 31, 2024 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
May 29, 2024 05:43AM Arrowhead Pharmaceuticals (ARWR) Presents New Phase 2 Data of Zodasiran
May 29, 2024 05:30AM Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
May 28, 2024 06:07AM Arrowhead Pharmaceuticals (ARWR) Presents New Phase 2 Data of Plozasiran
May 28, 2024 06:04AM Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
May 20, 2024 06:02AM Arrowhead Pharmaceuticals (ARWR) Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
May 20, 2024 06:00AM Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
May 9, 2024 04:01PM Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
May 2, 2024 04:02PM Arrowhead Pharmaceuticals (ARWR) Earns $50M Milestone from Royalty Pharma (RPRX)
May 2, 2024 04:01PM Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
Apr 29, 2024 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
Apr 26, 2024 07:30AM Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
Apr 24, 2024 04:01PM Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Apr 24, 2024 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Initiates Phase 1/2a Study of ARO-CFB
Apr 24, 2024 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Apr 7, 2024 09:00AM Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Apr 1, 2024 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 25, 2024 08:00AM Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Mar 8, 2024 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Mar 4, 2024 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
Feb 6, 2024 04:01PM Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
Jan 22, 2024 04:01PM Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
Dec 29, 2023 04:01PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 21, 2023 07:30AM Arrowhead Pharmaceuticals Inc. (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB
Dec 21, 2023 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
Dec 20, 2023 07:30AM Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nov 29, 2023 04:01PM Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
Nov 28, 2023 07:31AM Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
Nov 28, 2023 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
Nov 21, 2023 04:01PM Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
Nov 16, 2023 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
Nov 13, 2023 09:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
Nov 13, 2023 09:30AM Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
Nov 6, 2023 07:30AM Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
Nov 2, 2023 07:30AM Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
Oct 3, 2023 04:01PM Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
Sep 27, 2023 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 11, 2023 07:30AM Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
Sep 1, 2023 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
Aug 7, 2023 04:01PM Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
Jul 24, 2023 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results
Jul 17, 2023 07:32AM Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
Jul 17, 2023 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
Jul 6, 2023 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jun 27, 2023 07:31AM Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
Jun 27, 2023 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
Jun 24, 2023 08:15AM Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
Jun 6, 2023 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
View More Recent Stories View Older Stories